Results 91 to 100 of about 259 (175)

Emerging Paediatric Uses of Dupilumab Beyond Approvals

open access: yesClinical &Experimental Allergy, EarlyView.
Dupilumab, through IL‐4Rα blockade, shows promising efficacy beyond approved indications in paediatric diseases driven by T2 inflammation. Emerging evidence—mainly from small studies—supports improvements in disease severity and quality of life, highlighting its potential as a targeted, steroid‐sparing therapy while underscoring the need for ...
Simone Foti Randazzese   +11 more
wiley   +1 more source

Progress in the application of omalizumab in the treatment of chronic inducible urticaria

open access: yesPifu-xingbing zhenliaoxue zazhi
Chronic inducible urticaria (CIndU) is a chronic urticaria caused by unique triggers, manifested by wheals and angioedema as common symptoms. Omalizumab is a recombinant humanized anti-IgE antibody, which is currently listed as the third-line treatment ...
CHEN Ziyan   +8 more
doaj   +1 more source

In chronic spontaneous urticaria soluble FcεRI is elevated and linked to atopy and chronic inducible urticaria

open access: yesClinical and Translational Allergy, 2023
Moñino‐Romero, Sherezade   +23 more
openaire   +6 more sources

Processionary Moth Exposure in Europe: Toxic–Irritant and Immunoglobulin E‐Mediated Endotypes, Diagnosis and Management

open access: yesClinical &Experimental Allergy, EarlyView.
Most reactions are toxic–irritant, driven by epithelial injury and neuro‐inflammatory activation. IgE‐mediated allergy is less common but may cause immediate systemic reactions. Endotype differentiation guides diagnosis, risk stratification and management.
Prasad Dasari   +9 more
wiley   +1 more source

Fibrillar‐Type Dermatitis Herpetiformis: An Underrecognized Variant That Is Rarely Associated With Celiac Disease and Lacking Epidermal Transglutaminase Deposition: A Report of Two Cases

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Dermatitis herpetiformis (DH) is a rare, intensely pruritic cutaneous manifestation of celiac disease (CD), typically presenting with excoriated papulovesicular lesions on extensor surfaces. DH is associated with IgA autoantibodies against epidermal transglutaminase (eTG), which form granular immune deposits in the papillary dermis and induce ...
Jeffrey Damman   +5 more
wiley   +1 more source

Inborn errors of immunity in children with neuroinflammation

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
Abstract Inborn errors of immunity (IEIs), an expanding group of monogenic disorders with diverse clinical manifestations, are increasingly recognized to include neuroinflammatory disease. Examples of diseases included under this umbrella are Aicardi–Goutières syndrome, deficiency of adenosine deaminase 2, familial haemophagocytic lymphohistiocytosis ...
Eppie M Yiu   +5 more
wiley   +1 more source

Managing Chronic Urticaria: Quo Vadis?

open access: yesEuropean Medical Journal Dermatology, 2020
Chronic urticaria (CU) is one of the most commonly diagnosed skin conditions. CU is characterised by the presence of recurrent wheals and/or angioedema and intense pruritus persisting for at least 6 weeks.
Elena Petkova, Maria Staevska
doaj  

How Do I Measure up? Social Influence and L2 Motivation in the Algorithmic Age

open access: yesInternational Journal of Applied Linguistics, EarlyView.
ABSTRACT Comparative thinking is a fundamental human drive and a hallmark of contemporary life. For social action, such as the learning and use of additional languages, a target for appraisal (an L2 attribute) is evaluated in relation to a comparison standard (an appraiser's standpoint).
Alastair Henry, Meng Liu
wiley   +1 more source

Clinical Characteristics, Investigations and Treatment in Children with Chronic Urticaria: An Observational Study

open access: yesMedicina
Background and Objectives: The guidelines for chronic urticaria in children contain recommendations that are often based on adult studies. The diagnostic pathway has not been standardized and the effectiveness of anti-H1, omalizumab, montelukast, and ...
Enrico Vito Buono   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy